Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.60 |
| ▸ | CTSK | P43235 | 5/20 | 0.60 |
| ▸ | CTSB | P07858 | 3/20 | 0.60 |
| ▸ | CTSL | P07711 | 2/20 | 0.60 |
| ▸ | CTSD | P07339 | 1/20 | 0.58 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.57 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.57 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.57 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.57 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.57 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.57 |
| ▸ | REN | P00797 | 3/20 | 0.55 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.55 |
| ▸ | AKT1 | P31749 | 1/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29770301 | 0.96 | CTSS (0.60) | CTSSCTSKCTSBCTSLCTSD | |
| SCHEMBL11661865 | 0.91 | CTSD (0.67) | CTSSCTSKCTSBCTSLCTSD | |
| SCHEMBL28961339 | 0.91 | CTSD (0.67) | CTSSCTSKCTSBCTSLCTSD | |
| SCHEMBL29770339 | 0.91 | CTSK (0.61) | CTSSCTSKCTSBCTSDPSEN1 | |
| SCHEMBL29832567 | 0.91 | CTSK (0.61) | CTSSCTSKCTSBCTSDPSEN1 | |
| SCHEMBL24049786 | 0.90 | CTSK (0.71) | CTSSCTSKCTSBCTSLCTSD | |
| SCHEMBL26269169 | 0.90 | CTSK (0.71) | CTSSCTSKCTSBCTSLCTSD | |
| SCHEMBL8651650 | 0.90 | CTSK (0.71) | CTSSCTSKCTSBCTSLCTSD | |
| SCHEMBL24050003 | 0.89 | CTSS (0.66) | CTSSCTSKCTSBCTSLCTSD | |
| SCHEMBL4386421 | 0.89 | CTSS (0.65) | CTSSCTSKCTSBCTSLCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11396497-B2 | Proteasome inhibitors | NEW MEXICO TECH UNIVERSITY RESEARCH PARK CORPORATION (US) | 2022-07-26 | — | — | US | disclosed |
| US-6342582-B1 | PURIFICATION AND/OR BIOSYNTHESIS OF OLIGOPEPTIDES IN PRESENCE OF A PHENOL OR MIXTURE; DEBLOCKING, AMIDATION; VACCINES, DRUGS, FOOD, AGRICULTURE | RHODIA CHIMIE (FR) | 2002-01-29 | — | — | US | disclosed |
| US-5798443-A | MEDIUM COMPRISING WATER IMMISCIBLE DILUENT AND HYDROXYAROMATIC COMPOUND | RHONE-POULENC CHIMIE (FR) | 1998-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11396497-B2 | Proteasome inhibitors | TP53, CDKN1A, PSME1 | CTSS 1321/4885CTSK 646/4885CTSB 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.